

REPORT ON THE RESEARCH UNIT:
NF-kappaB, Différenciation et Cancer
(OncokappaB)

UNDER THE SUPERVISION OF THE
FOLLOWING INSTITUTIONS AND
RESEARCH BODIES:
Université Paris Descartes

EVALUATION CAMPAIGN 2017-2018
GROUP D



In the name of Hcéres¹:

Michel Cosnard, President

In the name of the expert committee²:

Neil Perkins, Chairman of the committee

Under the decree No.2014-1365 dated 14 November 2014,

¹ The president of Hcéres "countersigns the evaluation reports set up by the expert committees and signed by their chairman." (Article 8, paragraph 5);

² The evaluation reports "are signed by the chairman of the expert committee". (Article 11, paragraph 2).

This report is the sole result of the unit's evaluation by the expert committee, the composition of which is specified below. The assessments contained herein are the expression of an independent and collegial reviewing by the committee.

UNIT PRESENTATION

Unit name: NF-kappaB, Différenciation et Cancer

Unit acronym: OncokappaB

Requested label: EA

Application type: Renewal

Current number: 7324

**Head of the unit
(2017-2018):** Ms Véronique BAUD

**Project leader
(2019-2023):** Ms Véronique BAUD

Number of teams or themes: 1

COMMITTEE MEMBERS

Chair: Mr Neil PERKINS, University of Newcastle, UK

Experts: Ms Lucie KARAYAN-TAPON, CHU Poitiers (representative of CNU)

Ms Simona SACCANI, IRCAN-Nice

HCERES scientific officer:

Mr Théophile OHLMANN

Representatives of supervising institutions and bodies:

Ms Catherine LABBE JULLIE, Université Paris Descartes

Mr Michel VIDAL, Université Paris Descartes

INTRODUCTION

HISTORY AND GEOGRAPHICAL LOCATION OF THE UNIT

The unit was created in 2014 with Ms Veronique Baud as director. Originally located at the Institut Cochin it relocated to the Faculté de Pharmacie de Paris in December 2016.

MANAGEMENT TEAM

Unit head is Ms Veronique Baud and deputy head is Mr Thierry Molina.

HCERES NOMENCLATURE

SVE5

SCIENTIFIC DOMAIN

The focus of the unit is the molecular characterisation and treatment of B-cell haematopoietic malignancies, with particular emphasis on the role of the RelB NF-kappaB subunit.

UNIT WORKFORCE

Unit workforce	Number 30/06/2017	Number 01/01/2019
Permanent staff		
Full professors and similar positions	3	3
Assistant professors and similar positions	2	2
Full time research directors (Directeurs de recherche) and similar positions	1	1
Full time research associates (Chargés de recherche) and similar positions	0	0
Other scientists ("Conservateurs, cadres scientifiques des EPIC, fondations, industries, etc.")	1	1
High school teachers	0	0
Supporting personnel (ITAs, BIATSSs and others, notably of EPICs)	3 (0.8 FTE)	3
TOTAL permanent staff	10	10
Non-permanent staff		
Non-permanent professors and associate professors, including emeritus		
Non-permanent full time scientists, including emeritus, post-docs	1	
Non-permanent supporting personnel		

PhD Students	5	
TOTAL non-permanent staff	6	
TOTAL unit	16	

GLOBAL ASSESSMENT OF THE UNIT

The focus of the 'NF-kappaB, Différenciation et Cancer' based in the Faculté de Pharmacie de Paris at the Université Paris Descartes is the role of the RelB NF-kappaB subunit in B-cell malignancies. Since the previous evaluation report, the unit has made significant progress in this area. The future projects data have the potential to have a significant impact both in our understanding of the role of NF-kappaB in cancer but, importantly, in the treatment of patients with this disease. The strong links between the basic and clinical research are particularly noteworthy. The unit has been very productive both scientifically and clinically. There is good synergy between the basic research and clinical activities that has led to important scientific discoveries of direct relevance to the treatment of patients with B-cell malignancies. This is reflected in the high number of scientific and clinical articles and book chapters. The research being performed is novel and of an international standard, leading to publications in leading journals in the field. Furthermore, the unit is actively engaged in translating these findings into the clinic, both through the ability to access patient material and leading clinical trials. The unit has been successful in attracting European and National funding. Members of the unit are active participants in the scientific community. This is reflected by membership of editorial boards, acting as manuscript reviewers and participation in other peer review activities. In addition, members of the unit are invited to speak at scientific symposia. The unit is therefore very actively engaged at all levels of scientific and clinical work.

During this period the unit successfully relocated from the Institut Cochin to the Faculté de Pharmacie de Paris in December 2016, where it has now established a productive and thriving work environment. Overall the unit is performing basic and clinical research to a high, international standard.

The evaluation reports of Hceres
are available online: www.hceres.com

Evaluation of clusters of higher education and research institutions
Evaluation of higher education and research institutions
Evaluation of research
Evaluation of doctoral schools
Evaluation of programmes
International evaluation and accreditation



2 rue Albert Einstein
75013 Paris, France
T. 33 (0)1 55 55 60 10

hceres.com

[@Hceres_](https://twitter.com/Hceres_)

[Hcéres](https://www.youtube.com/Hceres)

